Elona Begvarfaj

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Chronic Rhinosinusitis

Systematic Review

Ultrasound Guided

Top Venues

Journal of personalized medicine

Journal of immunology research

Expert opinion on drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Carlo Cavaliere, Simonetta Masieri, Elona Begvarfaj, Antonella Loperfido, Silvia Baroncelli, Francesca Cascone, Andrea Ciofalo
Long-Term Perspectives on Chronic Rhinosinusitis with Nasal Polyps: Evaluating Recurrence Rates after Functional Endoscopic Sinus Surgery in the Biologics Era-A 5-Year Follow-Up Study. Journal of personalized medicine 14 (3) (2024)
Carlo Cavaliere, Simonetta Masieri, Elona Begvarfaj, Antonella Loperfido, Silvia Baroncelli, Francesca Cascone, Andrea Ciofalo
Long-Term Perspectives on Chronic Rhinosinusitis with Nasal Polyps: Evaluating Recurrence Rates after Functional Endoscopic Sinus Surgery in the Biologics Era-A 5-Year Follow-Up Study. Journal of personalized medicine 14 (3) (2024)
Antonella Loperfido, Carlo Cavaliere, Elona Begvarfaj, Andrea Ciofalo, Giovanni D'Erme, Marco De Vincentiis, Antonio Greco, Stefano Millarelli, Gianluca Bellocchi, Simonetta Masieri
The Impact of Antibiotics and Steroids on the Nasal Microbiome in Patients with Chronic Rhinosinusitis: A Systematic Review According to PICO Criteria. Journal of personalized medicine 13 (11) (2023)
Antonella Loperfido, Andrea Ciofalo, Carlo Cavaliere, Elona Begvarfaj, Francesca Cascone, Giacomo Alfonzo, Rosalba Cadeddu, Stefano Millarelli, Gianluca Bellocchi, Antonio Greco, Marco de Vincentiis, Simonetta Masieri
Dupilumab's Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life. Journal of immunology research 2023 (2023)
Carlo Cavaliere, Cristoforo Incorvaia, Elona Begvarfaj, Maria Patrizia Orlando, Rosaria Turchetta, Angela Musacchio, Massimo Ralli, Andrea Ciofalo, Antonio Greco, Marco de Vincentiis, Simonetta Masieri
The safety of sublingual immunotherapy, can the rare systemic reactions be prevented? Expert opinion on drug safety 20 (3) (2021)